DLA Piper leverages its international network to assist its clients with EU marketing authorisations, data transparency, and mandates concerning the public procurement of medicines. Dividing his time between Brussels and Rome, Marco de Morpurgo leads the team, regularly advising on sector specific behavioural and compliance related matters; he is also known for his extensive knowledge of national and EU regulations governing the pharma and biotech industries.
Legal 500 Editorial commentary
Key clients
- Medtronic
- Sanofi
- Syneos Health
- Bristol Myers Squibb
- ResMed
- Takeda
- Incyte
- Philip Morris International
- GlaxoSmithKline
- Novartis
- Ipsen
- Gilead
- WuXi Apptec
- Medica Group
- argenx
- Sarepta Therapeutics
- Amgen
Work highlights
- Assisted argenx BV with setting up a global distribution network for its autoimmune disease products. This involved reviewing distribution agreements in over 25 jurisdictions, and ensuring compliance with EU competition law.
- Advising Iovance Biotherapeutics on its acquisition of worldwide rights to Proleukin from Clinigen LImited, with a £166.7m upfront payment and potential milestone payments and royalties.
- Assisted Reata Pharmaceuticals with the preparation for the launch of a pipeline medicinal product in the EU and the UK. The team advised on market access, pricing, and reimbursement, contract drafting, supply chain management, compliance with Key Opinion Leaders, MSLs, and healthcare professionals, along with corporate and employment matters.
Practice head
The lawyer(s) leading their teams.
Marco de Morpurgo